Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open-label, global, multicohort trial—evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Solange, Dziadziuszko, Rafal, Morabito, Alessandro, Felip, Enriqueta, Gadgeel, Shirish M., Cheema, Parneet, Cobo, Manuel, Andric, Zoran, Barrios, Carlos H., Yamaguchi, Masafumi, Dansin, Eric, Danchaivijitr, Pongwut, Johnson, Melissa, Novello, Silvia, Mathisen, Michael S., Shagan, Sarah M., Schleifman, Erica, Wang, Jin, Yan, Mark, Mocci, Simonetta, Voong, David, Fabrizio, David A., Shames, David S., Riehl, Todd, Gandara, David R., Mok, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499854/
https://www.ncbi.nlm.nih.gov/pubmed/35995953
http://dx.doi.org/10.1038/s41591-022-01933-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499854/
https://www.ncbi.nlm.nih.gov/pubmed/35995953
http://dx.doi.org/10.1038/s41591-022-01933-w

Ejemplares similares